MEK is a promising target in the basal subtype of bladder cancer.

Merrill, Nathan M; Vandecan, Nathalie M; Day, Kathleen C; Palmbos, Phillip L; Day, Mark L; Udager, Aaron M; Merajver, Sofia D; Soellner, Matthew B

Merrill, Nathan M; Vandecan, Nathalie M; Day, Kathleen C; Palmbos, Phillip L; Day, Mark L; Udager, Aaron M; Merajver, Sofia D; Soellner, Matthew B.

Afiliação

Merrill NM; Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Vandecan NM; University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA.
Day KC; Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Palmbos PL; University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA.
Day ML; Department of Urology, University of Michigan, Ann Arbor, MI, USA.
Udager AM; Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Merajver SD; University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA.
Soellner MB; Department of Urology, University of Michigan, Ann Arbor, MI, USA.

Oncotarget ; 11(44): 3921-3932, 2020 Nov 03.

Article em En | MEDLINE | ID: mdl-33216841

Palavras-chave

3D culture; MEK inhibition; basal bladder cancer; bladder cancer; drug screen

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Oncotarget Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google